GSK Disagrees With Court Ruling to Allow Plaintiff-Expert Testimony in Goetz Case
24 March 2023 - 9:52PM
Dow Jones News
By Joe Hoppe
GSK PLC said Friday that it disagrees with a ruling in the Goetz
case by the California state court late Thursday to allow the
plaintiff's experts to testify, and said there is no consistent or
reliable evidence that ranitidine increases the risk of any
cancer.
The pharma major said the scientific consensus is that
ranitidine--the active substance in Zantac, a heartburn treatment
that both GSK and Sanofi SA had marketed--wasn't carcinogenic,
following 13 epidemiological studies.
The company said the litigation is still at an early stage, and
the decision relates only to the question of whether the
plaintiff's experts can testify at trial in the Goetz case, not
that the court agrees with the plaintiff's experts.
GSK said it will press additional defenses and said the
plaintiff still needs to prove his case at trial.
It added that the ruling doesn't affect other state cases, or
the December 2022 Daubert ruling.
In December, a U.S. judge dismissed a series of lawsuits around
Zantac. The lawsuits--which were measured in the tens of
thousands--alleged Zantac could cause cancer. The judge concluded
on Dec. 6 that there was no scientific evidence to support the
claim that Zantac's active substance ranitidine was in fact
carcinogenic.
Shares at 1011 GMT were down 56.8 pence, or 4%, at 1,380.6
pence.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
March 24, 2023 06:37 ET (10:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
